7 results on '"Furusyo, N."'
Search Results
2. Short‐term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct‐acting anti‐viral treatment
3. Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C
4. Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis? Authors’ reply
5. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study
6. Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C
7. Serum WFA+-M2 BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.